Introduction
Methods
Study design and participants
Questionnaire survey and assessment of eczema
Candidate genes and single nucleotide polymorphisms
Gene | SNP | Chromosome position | Location | Allele a | MAF b |
---|---|---|---|---|---|
IL13 | rs20541 | 5:132660272 | Exon 4 | G/A | 0.34/0.20/0.20 |
IL4 | rs2243250 | 5:132673462 | Promoter | T/C | 0.21/T, 0.15/0.36 c |
MS4A2 | rs1441586 | 11:60088555 | Promoter | T/C | 0.35/0.44/0.49 |
MS4A2 | rs569108 | 11:60095631 | Exon7 | A/G | 0.18/0.03/0.17 |
IL4RA | rs1805010 | 16:27344882 | Exon 5 | A/G | 0.50/0.45/0.48 |
IL4RA | rs1801275 | 16:27363079 | Exon 12 | A/G | 0.18/0.20/A, 0.34 d |
Genotyping
Statistical analysis
Results
Associations of epidemiologic factors with eczema
Phenotypes | Eczema n (%) | Non-eczema n (%) | P value a | OR (95% CI) b |
---|---|---|---|---|
Gender | ||||
Boy | 95 (56.9) | 212 (49.4) | 1 | |
Girl | 72 (43.1) | 217 (50.6) | 0.20 | 0.78 (0.53, 1.14) |
Gestational age (wk) | ||||
< 37 | 3 (1.8) | 18 (4.2) | 1 | |
37–39 | 126 (75.0) | 293 (68.3) | 0.44 | 1.84 (0.39, 8.61) |
≥ 40 | 39 (23.2) | 118 (27.5) | 0.64 | 1.47 (0.30, 7.15) |
Birth weight (g) | ||||
< 2500 | 2 (1.2) | 14 (3.3) | 1 | |
2500–4000 | 152 (90.5) | 377 (87.9) | 0.44 | 2.07 (0.32, 13.24) |
≥ 4000 | 14 (8.3) | 38 (8.9) | 0.48 | 2.04 (0.28, 14.68) |
Delivery mode | ||||
Vaginal | 44 (26.2) | 105 (24.5) | 1 | |
Cesarean section | 124 (73.8) | 324 (75.5) | 0.31 | 0.80 (0.51, 1.23) |
Parity | ||||
None | 158 (94.0) | 390 (90.9) | 1 | |
≥ 1 | 10 (6.0) | 39 (9.1) | 0.16 | 0.57 (0.26, 1.25) |
Antibiotic use | ||||
No | 72 (42.9) | 255 (60.0) | 1 | |
Yes | 96 (57.1) | 170 (40.0) | 0.00 | 2.02 (1.37, 2.98) |
Home pet sitting c | ||||
No | 133 (79.2) | 355 (83.5) | 1 | |
Yes | 35 (20.8) | 70 (16.5) | 0.51 | 1.18 (0.72, 1.92) |
In-home secondhand smoke exposure | ||||
No | 66 (39.3) | 213 (50.2) | 1 | |
Yes | 102 (60.7) | 211 (49.8) | 0.16 | 1.32 (0.89, 1.96) |
Home decoration | ||||
No | 152 (91.0) | 394 (92.7) | 1 | |
Yes | 15 (9.0) | 31 (7.3) | 0.43 | 1.31 (0.67, 2.57) |
Parental atopy d | ||||
No | 120 (72.3) | 346 (81.6) | 1 | |
Yes | 46 (27.7) | 78 (18.4) | 0.06 | 1.53 (0.98, 2.39) |
Maternal education | ||||
Middle school or lower | 3 (1.8) | 15 (3.5) | 1 | |
High school | 14 (8.3) | 57 (13.3) | 0.87 | 1.13 (0.24, 5.40) |
College or higher | 151 (89.9) | 356 (83.2) | 0.43 | 1.81 (0.42, 7.85) |
Paternal education | ||||
Middle school or lower | 2 (1.2) | 6 (1.4) | 1 | |
High school | 17 (10.2) | 51 (12.0) | 0.65 | 0.64 (0.09, 4.45) |
College or higher | 148 (88.6) | 367 (86.6) | 0.44 | 0.48 (0.07, 3.11) |
Family income (CNY) | ||||
< 100 K | 44 (26.3) | 129 (30.2) | 1 | |
≥ 100 K | 101 (60.5) | 226 (52.9) | 0.24 | 1.32 (0.84, 2.08) |
Unknown | 22 (13.2) | 72 (16.9) | 0.77 | 0.91 (0.49, 1.70) |
Associations of candidate genes with eczema
Genotypes | Eczema n (%) | Non-eczema n (%) | P value a | OR (95% CI) |
---|---|---|---|---|
IL13 rs20541 | ||||
AA | 13 (7.7) | 52 (12.1) | 1 | |
AG | 79 (47.0) | 197 (46.0) | 0.13 | 1.70 (0.86, 3.36) |
GG | 76 (45.2) | 179 (41.8) | 0.10 | 1.77 (0.90, 3.49) |
IL4 rs2243250 | ||||
CC | 8 (4.8) | 21 (4.9) | 1 | |
CT | 55 (32.7) | 137 (31.9) | 0.73 | 1.17 (0.48, 2.88) |
TT | 105 (62.5) | 271 (63.2) | 0.83 | 1.10 (0.46, 2.62) |
MS4A2 rs1441586 | ||||
CC | 20 (11.9) | 46 (10.8) | 1 | |
CT | 70 (41.7) | 212 (49.8) | 0.73 | 1.14 (0.53, 2.46) |
TT | 78 (46.4) | 168 (39.4) | 0.41 | 1.42 (0.61, 3.30) |
MS4A2 rs569108 | ||||
AA | 120 (71.4) | 285 (66.4) | 1 | |
AG | 38 (22.6) | 137 (31.9) | 0.26 | 0.74 (0.44, 1.25) |
GG | 10 (6.0) | 7 (1.6) | 0.02 | 4.66 (1.32, 16.44) |
IL4RA rs1805010 | ||||
AA | 44 (26.3) | 109 (25.6) | 1 | |
AG | 79 (47.3) | 209 (49.1) | 0.82 | 0.95 (0.61, 1.49) |
GG | 44 (26.3) | 108 (25.4) | 0.67 | 1.12 (0.67, 1.88) |
IL4RA rs1801275 | ||||
AA | 107 (63.7) | 288 (67.3) | 1 | |
AG | 59 (35.1) | 127 (29.7) | 0.10 | 1.41 (0.94, 2.10) |
GG | 2 (1.2) | 13 (3.0) | 0.25 | 0.41 (0.09, 1.86) |
Interaction between antibiotic use and MS4A2 rs569108 on eczema
Antibiotic use | rs569108 | Eczema n (%) | Non-eczema n (%) | P value a | OR(95%CI) |
---|---|---|---|---|---|
– | AA/AG | 67 (39.9%) | 251 (59.1%) | 1 | |
– | GG | 5 (3.0%) | 4 (0.9%) | 0.03 | 4.68 (1.22,17.92) |
+ | AA/AG | 91 (54.2%) | 167 (39.3%) | 0.00 | 2.04 (1.41,2.96) |
+ | GG | 5 (3.0%) | 3 (0.7%) | 0.01 | 6.24 (1.46,26.79) |